Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05865054 · ClinicalTrials.gov registry record
Vascular MRI Evaluation in Giant Cell Arteritis (VEGA)
A clinical trial of Giant Cell Arteritis, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- 400
- Enrollment target
- 4
- Study locations
NCT05865054: Recruiting study of Giant Cell Arteritis, sponsored by University of Pennsylvania.
NCT05865054 is a study of Giant Cell Arteritis that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 400 participants, below the 993-participant average among 7 other Giant Cell Arteritis trials with a reported enrollment target (60% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05865054, a study of Giant Cell Arteritis, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 4
- Study locations
Study Summary
The research study is being conducted to determine the utility of magnetic resonance imaging (MRI) in identifying inflammation of arteries supplying blood to the head, brain, and eyes. The target population includes patient with suspected giant cell arteritis (GCA; temporal arteritis).
Primary Outcome
Enhancement of cranial vessel wall, orbital structures, or other cranial structures. Scores range from 0 to 3; 0 being no inflammation and 3 being more enhancement or inflammation.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Magnetic Resonance Imaging (MRI)
Study Locations (4)
Minnesota
- Mayo Building and Gonda Building - Rochester
Pennsylvania
- 3400 Civic Center Blvd - Philadelphia
Ontario
- St. Joseph's Healthcare Hamilton - Hamilton
Würzburg
- University Hospital Wuerzburg - Würzburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2020-07-29 |
| Est. Completion | 2033-07 |
What NCT05865054 shows while recruiting
NCT05865054 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 993-participant average among 7 other Giant Cell Arteritis trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Giant Cell Arteritis appearing as the primary indexed condition, and to 1 intervention - of which Magnetic Resonance Imaging (MRI) is the first listed.
NCT05865054 reports a single indexed study location in Minnesota, Pennsylvania, Ontario.
Frequently Asked Questions
What is clinical trial NCT05865054 about?
NCT05865054 is a clinical study titled "Vascular MRI Evaluation in Giant Cell Arteritis (VEGA)". The research study is being conducted to determine the utility of magnetic resonance imaging (MRI) in identifying inflammation of arteries supplying blood to the head, brain, and eyes. The target population includes patient with suspected giant cell arteritis (GCA; temporal arteritis).
What is the current status of trial NCT05865054?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2020-07-29. Estimated completion is 2033-07.
What conditions does trial NCT05865054 study?
This clinical trial studies the following conditions: Giant Cell Arteritis.
What interventions are being tested in trial NCT05865054?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05865054?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05865054 being conducted?
This trial has 4 study locations across Minnesota, Pennsylvania, Ontario, Würzburg. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Giant Cell Arteritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
One-Time DNA Study for Vasculitis
RECRUITING
-
VCRC Tissue Repository
RECRUITING
-
Abatacept for the Treatment of Giant Cell Arteritis
RECRUITING · Phase 3
-
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
RECRUITING
-
Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis
COMPLETED · Phase 2
-
Vasculitis Illness Perception (VIP) Study
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI